Human Erythropoietin Injection (EPO) 3000 IU

Overview

Human Erythropoietin Injection (EPO) is a recombinant protein therapy designed to stimulate the production of red blood cells (RBCs) in the bone marrow. It is commonly prescribed to treat anemia associated with chronic kidney disease, chemotherapy, or certain medical conditions where natural erythropoietin levels are insufficient.

Active Ingredient

Recombinant Human Erythropoietin (rHuEPO)

Strength: 3000 IU per vial

Mechanism of Action

Erythropoietin is a glycoprotein hormone naturally produced by the kidneys. This synthetic version mimics its biological function, binding to erythroid progenitor cells in the bone marrow and promoting their survival, proliferation, and differentiation into mature red blood cells.

Indications

Anemia due to chronic renal failure (dialysis or pre-dialysis patients)

Anemia induced by chemotherapy in cancer patients

Anemia in patients with HIV treated with zidovudine

Pre- and post-surgical use in specific cases to reduce the need for blood transfusions

Benefits

Increases hemoglobin and hematocrit levels

Reduces symptoms of anemia (fatigue, weakness, shortness of breath)

Improves quality of life and exercise tolerance

Decreases dependence on blood transfusions

Dosage Form

Sterile injection, 3000 IU per vial/syringe (subcutaneous or intravenous administration depending on clinical need)

Manufacturer

Harbin Pharmaceutical Group (HPGC) – Biotech Division

Storage

Store refrigerated at 2–8°C.

Do not freeze.

Protect from light.

Important Notes

Use only under medical supervision.

Dosage and treatment duration vary according to patient’s hemoglobin levels and clinical condition.

Regular monitoring of hemoglobin and blood pressure is necessary.

Potential side effects: hypertension, flu-like symptoms, headache, joint pain, or increased risk of thrombotic events.